Biosimilars Market Transparency Market Research, All Rights Reserved

Transcription

1 Biosimilars Market Biosimilars Market Segmentation by Product: Recombinant Glycosylated Proteins, Recombinant Non-glycosylated Proteins, and Recombinant Peptides; and Indication: Chronic Diseases, Oncology, Autoimmune Diseases, Infectious Diseases, Blood Disorders, Growth Hormone Deficiency, and Forecast,

2 Table of Content Sr. No. Content Chapter 1 Preface Chapter 2 Assumptions and Acronyms Chapter 3 Research Methodology Chapter 4 Executive Summary: Global Biosimilars Market Chapter 5 Market Overview Chapter 6 Market Outlook Chapter 7 Global Biosimilars Market Analysis and Forecast, by Product Chapter 8 Global Biosimilars Market Analysis and Forecast, by Indication Chapter 9 Global Biosimilars Market Analysis and Forecast, by Region Chapter 10 North America Biosimilars Market Analysis and Forecast Chapter 11 Europe Biosimilars Market Analysis and Forecast Chapter 12 Asia Pacific Biosimilars Market Analysis and Forecast Chapter 13 Latin America Biosimilars Market Analysis and Forecast Chapter 14 Middle East & Africa Biosimilars Market Analysis and Forecast Chapter 15 Competition Landscape

3 Biosimilars Market - Snapshot Biosimilars can be defined as a biologic medical product, which is considered to be similar to already approved biologic. These biosimilars are approved based on their efficacy, quality, safety, and the same standards of pharmaceutical quality that apply to all biologic medicines. Biosimilars are the copy versions of biologics, which have reached the end of patent protection. Aging population and changing societal behavior are the key factors contributing to the increase in prevalence of chronic diseases.

4

5 Reports Highlights Innovations in monoclonal antibodies (mabs) are expected in the biosimilars market landscape in the near future. The biosimilars market is expected to expand at a high CAGR of ~23% during the forecast period. The global biosimilars market was valued at ~US$ 8 Bn in 2018 and is projected to expand at a high CAGR from 2019 to Manufacturers are gaining business stability by increasingly innovating in biosimilars catering to cancer patients and are driving down costs of medicines. Request For Sample

6

7 Continue.. Healthcare companies are increasing their efficacy in hybridoma-based technology to develop improved mabs with the help of genetic engineering. The global biosimilars market is consolidated in terms of number of players. Key players operating in the global biosimilars market include Pfizer, Inc., Intas Pharmaceuticals Ltd., Biocon, Dr. Reddy s Laboratories Ltd., These players have adopted various strategies such as product portfolio expansion, investment in R&D, collaborations, and product launches to establish a strong geographic presence. Request For Brochure

8 Contact To know more about us, please visit our website: For sales queries or new topics us on: Thank You